InSphero

🎥 Peer-reviewed Publication by InSphero & FDA’s NCTR | Insights from the Authors In this interview, the first author, Lola Fäs, and the corresponding author, Dr. Bruno Filippi from our Liver Safety team share exclusive insights from the recent publication in Toxicological Sciences. 📄 What’s it about? In this video, our experts discuss the landmark research conducted by InSphero and scientists from the FDA’s National Center for Toxicological Research. They dive into the groundbreaking use of 3D liver microtissues in detecting drug-induced liver injury (#DILI) and share key findings, including: 🟢 Testing of 152 FDA-approved drugs with our 3D liver microtissues, which accurately predict #DILI, one of the leading causes of drug development discontinuation 🟢 How the technology correctly identified 90% of safe drugs and 80% of the withdrawn compounds. 🟢 The scalability of our Akura™ 384-well microplate system for early drug testing. 🎬 Watch the full interview to learn more about how InSphero’s technology drives safer, more efficient drug development. Read the full publication via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Wolfgang Moritz Filip Henzler Rositsa Hadzhipetrova Arumugham (Ragoo) Raghunathan Arnab China, PhD Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Anna Borgström Tina Žel Tong Weida, minjun chen, Friederike Wenz, Monika Tu, Katarzyna Sanchez, Natalia Zapiórkowska-Blumer, Hajnalka Varga, Karolina Kaczmarska, Maria Vittoria Colombo #DrugDevelopment #Toxicology #LiverToxicity #3DCellCulture #InSphero #FDA #PharmaInnovation

🔬 Struggling with conflicting DILI data in your pre-clinical animal studies? Wondering which species best predicts human responses? 🤔 InSphero’s 3D InSight™ XSpecies Liver Microtissues can help you navigate species-specific toxicity and improve your pre-clinical models. 🧬 By comparing different species under controlled invitro conditions, batch- and time-matched with our human Liver Microtissues, we support you in identifying the most predictive pre-clinical model or mitigating risks from animal study findings. 🔸 Rat Model: Multi-donor Sprague-Dawley primary hepatocytes with non-parenchymal cells (NPCs) 🐀 🔸 Mouse Model: Multi-donor C57/BL6 primary hepatocytes with NPCs 🐭 🔸 Dog Model: Single-donor Beagle primary hepatocytes with NPCs 🐕🦺 🔸 Monkey Model: Single-donor Cynomolgus primary hepatocytes with NPCs 🐒 🔸 Human Model: 10-donor primary human hepatocytes with NPCs 🧑🔬 Let us help you understand and predict species-specific toxicity for more reliable pre-clinical outcomes! Check out the website linked in the comments to learn more. 👇 Madhu Lal Nag, MBS PhD, Maria Vittoria Colombo, Bruno Filippi, Anna Borgström, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Paul Edgard Clémençon, Arumugham (Ragoo) Raghunathan, Bärbel Ulmer, Arnab China, Ph.D., Sue Grepper, PhD, Christine Schwenk, Rositsa Hadzhipetrova, Tina Žel #DILI #Hepatotoxicity #3DModels #PreclinicalResearch #InVitro #DrugDevelopment

🌟 OpenTox Virtual Conference 2024 is starting today! 🌟 Don’t forget to join us for an insightful presentation by Dr. Anna Borgström, Deputy VP of Liver Safety! 📅 Date: Wednesday, 27th November ⏰ Time: 11:50 AM (Session 7) 🎤 Title: Leveraging Human Liver Microtissue Systems for Hepatotoxicity Screening Early in Drug Discovery Anna will be sharing groundbreaking advancements in using high-density microplates for early hepatotoxicity screening in drug development. This is a fantastic opportunity to explore the future of liver safety and drug discovery! Don’t miss out on this invaluable opportunity to stay at the forefront of innovation in the field! Bruno Filippi, Maria Vittoria Colombo, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Paul Edgard Clémençon, Arumugham (Ragoo) Raghunathan, Bärbel Ulmer, Arnab China, Ph.D., Sue Grepper, PhD, Christine Schwenk, Rositsa Hadzhipetrova, Tina Žel #OpenTox2024 #LiverSafety #DrugDiscovery #PharmaceuticalResearch #InnovationInScience #ToxicityTesting #TheModelofExcellence™

🎉 Celebrating 10 years of excellence at InSphero! 🎉 🥂 Today, we’re thrilled to recognize Frauke Greve, Senior Product Manager of our spheroid microplate portfolio, for her decade of dedication and hard work!  🚀 Frauke is the driving force behind the development of cutting-edge plates, ensuring that we always have the best materials and processes in place to meet the needs of our customers and internal teams. Her professionalism, exceptional organization skills, and sense of humor make her the embodiment of the InSphero Model of Excellence. 👏 Dear Frauke, thank you for everything you do! Here’s to many more years of success together. 🙌 Jan Lichtenberg, Filip Henzler, Paul Edgard Clémençon, Madhu Lal Nag, MBS PhD, Olivier Frey, Lisa Hoelting, Tamara Häfeli, Ozlem Yavas Grining, Agnieszka Pawlowska, Judi Wardwell-Swanson, Bärbel Ulmer, Christine Schwenk, Arumugham (Ragoo) Raghunathan, Sue Grepper, PhD, Arnab China, Ph.D., Rositsa Hadzhipetrova, Tina Žel #InSphero #EmployeeAnniversary #TeamExcellence #ProductManagement #SpheroidMicroplates #Innovation #Gratitude 

🌟 Will you be attending the OpenTox Virtual Conference 2024? 🌟   Dr. Anna Borgström, Deputy VP of Liver Safety, will be presenting at the event! Title: Leveraging Human Liver Microtissue Systems for Hepatotoxicity Screening Early in Drug Discovery 📅 Date: Wednesday, 27th November ⏰ Time: 11:50 AM (Session 7) Anna’s session will showcase innovative advancements in using high-density microplates for early hepatotoxicity screening in drug development. This is a fantastic opportunity to dive into the future of liver safety and drug discovery! Don’t miss out – mark your calendars and join us for this must-attend presentation! Bruno Filippi, Maria Vittoria Colombo, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Paul Edgard Clémençon, Arumugham (Ragoo) Raghunathan, Bärbel Ulmer, Arnab China, Ph.D., Sue Grepper, PhD, Christine Schwenk, Rositsa Hadzhipetrova, Tina Žel #OpenTox2024 #LiverSafety #DrugDiscovery #PharmaceuticalResearch #InnovationInScience #ToxicityTesting

🔓 InSphero is proud to help #UNLOOC the future of drug discovery! As a leader in scalable #3D #invitro solutions, we are taking a pivotal role in the UNLOOC Chips JU Project, a €68M initiative to unlock the full potential of #organonchip systems for drug development and personalized medicine. Our use case focuses on creating #cryopreserved 3D in vitro organ models reflecting human #diversity, paired with advanced #AI-driven analysis tools. 🎤 Dr. Olivier Frey, member of the UNLOOC executive board and project leader at InSphero, highlights: “UNLOOC accelerates our efforts to unlock scalable, high-resolution solutions for inclusive drug testing.” Together with 51 partners, we’re redefining what’s possible in #invitro drug safety and efficacy testing! 🌍 👋 Read the full press release via the link in the comments 👇 microfluidic ChipShop GmbH AbbVie AlveoliX Beonchip ZEISS Microscopy Core Life Analytics CSEM BeCytes Biotechnologies Demcon IBEC's Core Facilities Centro de Investigación Príncipe Felipe (CIPF) LioniX International Lipotype INESC-ID Locsense Micronit TNO Nuromedia GmbH Okolab OST – Eastern Switzerland University of Applied Sciences Philips DDS Diagnostic SiliconGate Delft University of Technology Technische Universität Braunschweig Universidad de Zaragoza Universidad de Santiago de Compostela Maastricht University University College Cork Università di Pavia Viscofan BioEngineering Jobst Technologies GmbH - an IST AG company imec IMT-Bucharest #InSphero #UnlockPotential #UNLOOC #3DInVitro #Innovation

🚨 Only 2 Days Until American College of Toxicology (ACT) 2024! 🚨   Here’s where you can find us:   📍 Booth #503 — We’ll be showcasing our innovative 3D InSight™ Liver Microtissue Solutions!   👩🔬 Dr. Maria Vittoria Colombo will present her poster: Species-Specific Liver Microtissues: Translational Hepatotoxicity Assessment in Drug Development 📅 Monday, Nov 18 | 🕒 5:00–6:30 PM | Poster Board P405   👨🔬 Dr. Bruno Filippi will lead an Exhibitor-Hosted Session: In Vitro Hepatotoxicity Assessment with the 3D InSight™ Liver Microtissue Platform 📅 Tuesday, Nov 19 | 🕒 12:00–12:55 PM | Level 2, Room 204   Don’t miss this chance to learn how our cutting-edge models are advancing hepatotoxicity testing, driving more reliable and ethical preclinical research.   Looking forward to connecting with you in person!   To schedule a meeting, check the link in the comments. Paul Edgard Clémençon, Arumugham (Ragoo) Raghunathan, Anna Borgström, Lola Fäs, Katarzyna Sanchez, Monika Tu, Karolina Kaczmarska, Hajnalka Varga, Bärbel Ulmer, Arnab China, Ph.D., Sue Grepper, PhD, Christine Schwenk, Rositsa Hadzhipetrova, Tina Žel   #ACT2024 #Toxicology #DrugDevelopment #LiverModels #InVitroTesting #Hepatotoxicity #PreclinicalResearch #Pharma #InSphero

🎉Just a few days until American Association for the Study of Liver Diseases (AASLD)! We’re excited to present our latest research on anti-fibrotic treatments and clinical candidates for #MASH at this year’s conference. Join us for an in-depth look at cutting-edge methodologies and 3D human liver spheroids. Don’t miss these sessions! 📌 Poster Presentation Details: Sue Grepper, PhD Poster #1124 Title: Insight into the Efficacy of Clinical Anti-Fibrotic Compounds Using Digital Pathology with AI in a 3D Human MASH Model 🗓️Friday, Nov 15, 1:00–2:00 pm 📍Room: Hall C, Poster Hall Section: MASLD/MASH - Experimental: Basic Dr. Francisco Verdeguer Poster #3187 Title: Screening and Comparison of Current Clinical Candidates in MASH Using Human Liver Spheroids 🗓️Sunday, Nov 17, 1:00–2:00 pm 📍Room: Hall C, Poster Hall Section: MASLD/MASH – Therapeutics: Approved/Available Agents Join us in March 2025 for our third MASH CALL Initiative, to leverage our innovative approach to drug discovery, offering in-depth insights into: - The anti-steatotic and anti-fibrotic effects of your compounds - Comparative analysis with clinical candidates and reference standards Sue and Francisco will be happy to share more information about MASH-CALL at AASLD—don’t miss the chance to speak with them directly! Radina Kostadinova, PhD, Philip Vonschallen, Joel Zvick, Jesus Francisco Glaus Garzon, Arnab China, Ph.D., Christine Schwenk, Bärbel Ulmer, Paul Edgard Clémençon, Arumugham (Ragoo) Raghunathan, Rositsa Hadzhipetrova, Tina Žel #LiverMeeting #LiverHealth #Hepatology #3DCellCulture #DrugDiscovery #TheModelofExcellence™

🧐 Beyond the Average Patient: Integrating Population Diversity to Revolutionize Liver Safety in Drug Development at #IHICallDays Our Head of External Collaborations and Co-founder, Dr. Wolfgang Moritz will attend the Brokerage event for Innovative Health Initiative (IHI)’s 2025 calls from November 12 to 14 in Brussels, where he will present InSphero’s innovative approach to enhance population diversity in #preclinical research. 🔬 By using human liver microtissues from a wide range of human donors—including varying ages, sexes, races, and liver health profiles—we’re addressing gaps in #drugsafety that can lead to unexpected #livertoxicity in diverse populations. 🚀 Our approach involves testing compounds known to cause drug-induced liver injury (#DILI), applying pathology and biomarker profiling, and even developing an #AI-assisted DILI prediction scoring tool to identify high-risk profiles early. 🤩 Aligned with #IHICallDays, this initiative not only promotes patient safety but aims to create safer, more effective therapies across diverse populations. Excited to lead this next chapter in patient-centered drug development! 📅 Would you like to learn more and join our initiative? Register for the event via the link in comments 👇 Jan Lichtenberg Madhu Lal Nag, MBS PhD Paul Edgard Clémençon Arumugham (Ragoo) Raghunathan Arnab China, Ph.D. Bärbel Ulmer Christine Schwenk Sue Grepper, PhD Tina Žel Rositsa Hadzhipetrova

🎙️ How Are 3D Cell Cultures Revolutionizing Drug Testing? Don’t miss the second episode of Balancing the Future, the METTLER TOLEDO Laboratory Solutions podcast, featuring our CEO and co-founder, Dr. Jan Lichtenberg. He joins hosts Dana and Micah to explore how 3D cell cultures are revolutionizing drug testing and paving the way for personalized medicine. 🔍 Check out the podcast link in the comments👇 #3DCellCulture #BalancingTheFuture #Sustainability #Podcast